Searchable abstracts of presentations at key conferences in endocrinology

ea0081p756 | Thyroid | ECE2022

Radiofrequency and ethanol ablation for benign thyroid nodules: case series

Jimenez Torrecilla Pedro , Gonzalez Lazaro Paloma , Moreno Tirado Antonio , Montalban Mendez Cristina , Zhao Montero Benitez Maria , del Val Zaballos Florentino , Gomez Garcia Ines

Introduction: Thyroid nodule is a frequent condition, being diagnosed in up to 70% of subjects who had undergone thyroid ultrasound. Around 90-95% of them became being benign and, if the do not cause compressive symptoms or esthetical problems, they do not need specific therapy, only clinical follow up. Traditionally, thyroidectomy has been the main therapeutic option in these cases. Radiofrequency and ethanol ablations are recently introduced non-invasive therapies that permi...

ea0090ep694 | Pituitary and Neuroendocrinology | ECE2023

Thyrotropin-secreting pituitary tumor: a rare entity

Torrecilla Pedro Jimenez , Gonzalez Lazaro Paloma , Moreno Tirado Antonio , Montero Benitez Maria Zhao , Lomas Meneses Amparo , Del Val Zaballos Florentino , Contreras Pascual Cristina

TSH-secreting pituitary adenomas are a rare cause of hyperthyroidism. The diagnosis should be considered in all hyperthyroid patients, especially those with a diffuse goiter and no extrathyroidal manifestations of Graves’ disease. Most TSH-secreting adenomas secrete only TSH. Most patients have the typical symptoms and signs ofhyperthyroidism (eg, palpitations, tremor, heat intolerance), but a few patients have mild or even no hyperthyroid symptoms. Other clinical feature...

ea0090ep842 | Pituitary and Neuroendocrinology | ECE2023

Spontaneous involution of a cystic pituitary adenoma

Zhao Montero Benitez Maria , Gonzalez Lazaro Paloma , Moreno Tirado Antonio , Jimenez Torrecilla Pedro , Contreras Pascual Cristina , Del Val Zaballos Florentino , Lomas Meneses Amparo , Gomez Garcia Ines

Pituitary adenomas (PAs) account for 15-20% of intracranial tumors. PA with a cystic component are characterized in the MRI by a sellar, symmetrical, round or ovoid mass that enhances on T1- or T2-weighted images but does not concentrate gadolinium. We present the case of a 48-year-old man who in a headache study by Neurology requested a CT scan showing a cystic pituitary macroadenoma of 1.25cm confirmed by pituitary MRI. In the initial analysis, the pituitary function was pre...

ea0063p1061 | Pituitary and Neuroendocrinology 3 | ECE2019

Clinical features and endocrine evaluation of non-functioning pituitary adenomas at a secondary level hospital

Pascual Cristina Contreras , Lazaro Paloma Gonzalez , Fernandez Julia Silva , del Val Zaballos Florentino , Alfonso Francisco Javier Gomez , Agredos Alvaro Garcia-Manzanares Vazquez-de , Garcia Ines Rosa Gomez

Introduction: Non-functioning pituitary adenomas are relatively common. A large number of these tumors are asintomathic pituitary microadenomas, that are increasingly detected because of sensitive imaging techniques improves. Those tumors that require treatment are generally macroadenomas and come to medical attention because of mass effect (visual field defects, headache, …) and/or hypopituitarism.Objective: To assess non-functioning pituitary ade...

ea0063ep88 | Pituitary and Neuroendocrinology | ECE2019

Secondary amenorrhea as unique manifestation of acromegaly due to giant pituitary adenoma

Contreras Pascual Cristina , Gonzalez Lazaro Paloma , Silva Fernandez Julia , del Val Zaballos Florentino , Garcia-Manzanares Vaquez-de Agredos Alvaro , Javier Gomez Alfonso Francisco , Rosa Gomez Garcia Ines

Introduction: Pituitary adenomas are considered to be benign tumors that are diagnosed by its sympthoms (secondary to compression or hormonal secretion) or incidentally in an imaging technique performed because of another reason. ‘Silent’ somatotrophinomas are very rare. This type of adenoma is typically large and despite it presents with mild or no acromegalic features it usually develops hormone secretion.A case report: A 29-year-old spanish ...

ea0049ep456 | Diabetes (to include epidemiology, pathophysiology) | ECE2017

Response to stroke in diabetic versus non-diabetic patients. Should Diabetes education systematically include advise on stroke symptoms and the correct response to them?

Gonzalez-Lazaro Paloma , Silva-Fernandez Julia , Garcia-Ruiz Rafael , Garcia-Ruiz Rosa , Gomez-Alfonso Francisco Javier , Del Val-Zaballos Florentino , Torres-Arroyo Belvis , Gonzalez-Pereira Carolina

Introduction: Stroke is the second cause of death in the world and the first cause of disability. It is also the second cause of Diabetes-related death. The success of reperfusion therapies is time-dependent, with most delays being patient-related. We investigated the response to stroke in diabetic patients (DM), as their risk of stroke is increased by 1,8-6 times.Material and Methods: Consecutive patients with acute stroke or transient ischemic attack w...

ea0056p72 | Adrenal medulla | ECE2018

Genetics in pheochromocytoma and paraganglioma: a case series

Gonzalez Lazaro Paloma , Contreras Pacual Cristina , Silva Fernandez Julia , Torres Arroyo Belvis , Javier Gomez Alfonso Francisco , Del Val Zaballos Florentino , Gomez Garcia Ines , Garcia Manzanares Alvaro

Introduction: In most patients with familial history of pheochromocytoma/paraganglioma, leads in the majorty of cases to a postive genetic testing for mutations, and what’s more in those patients with no familial antecedents, about 10–25% carry a mutation in one related gene. In these cases other aspects like, bilaterality, multiplicity or location must be taken into account.Objective: The objective of the study was to discuss the importance of...

ea0056p761 | Neuroendocrinology | ECE2018

Recurrence of hyperprolactinemia after dopamine agonists withdrawal

Contreras Pascual Cristina , Gonzalez Lazaro Paloma , Silva Fernandez Julia , Gomez Garcia Ines , Maria Torres Arroyo Belvis , del Val Zaballos Florentino , Javier Gomez Alfonso Francisco , Garcia Manzanares Vazquez Alvaro

Introduction: Prolactinomas are the most common tumors among functional pituitary adenomas and they constitute 40% of all pituitary tumors. Dopamine agonists (DA) are considered the primary treatment of prolactinoma. DA can lead to complete remission (including eradicacion of the tumor), allowing discotinuation of treatment. So far, there aren’t clinical criteria with sufficient predictive value for long-term remission.Objective: To assess the effec...

ea0081ep293 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

HbA1c response after initiation of flash glucose monitoring in adults with diabetes

Tirado Antonio Moreno , Mendez Cristina Montalban , Montero Benitez Maria Zhao , Torrecilla Pedro Jimenez , Gonzalez Lazaro Paloma , Del Val Zaballos Florentino , Meneses Amparo Lomas , Gomez Alfonso Francisco Javier , Iglesias Maria Lopez , Gomez Garcia Ines

Introduction and Objective: Flash glucose monitoring is a form of interstitial glucose monitoring and it is indicated in patients with diabetes mellitus.The objetive of the study was to assess the effect of introducing flash glucose monitoring in adults with diabetes with respect to change in hemoglobin A1c (HbA1c).Material and methods: Prospective observational study of adults with diabetes in our center, in whom a prescription for a flash glucose monit...

ea0063gp209 | Diabetes: Pharmacotherapy | ECE2019

Efficacy and tolerability of dulaglutide in patients with type 2 diabetes: Experience on a secondary Hospital

Lazaro Paloma Gonzalez , Pascual Cristina Contreras , del Val Zaballos Florentino , Fernandez Julia Silva , Alfonso Francisco Javier Gomez , Arroyo Belvis Torres , de Agredos Alvaro Garcia Manzanares Vazquez , Garcia Ines Gomez

Introduction: Dulaglutide (Trulicity®) is a long-acting GLP-1 agonist that received US Food and Drug Administration (FDA) approval in 2014. Dulaglutide is a large sized molecule, which limits its renal clearance. This allows for once weekly dosing; which might improve patient compliance significantly. Extensive Phase III study data have been published with regard to dulaglutide, much of which was part of the AWARD studies, which provide evidence for its use in ...